Exact Sciences Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Exact Sciences stock.
View analyst ratings for Exact Sciences or view top-rated stocks.

12 Wall Street analysts have issued twelve-month target prices for Exact Sciences' shares. Their EXAS stock forecasts range from $50.00 to $155.00. On average, they anticipate Exact Sciences' share price to reach $101.33 in the next twelve months. This suggests a possible upside of 134.4% from the stock's current price.
View analysts' price targets for Exact Sciences or view top-rated stocks among Wall Street analysts.

Exact Sciences' stock was trading at $77.83 at the beginning of the year. Since then, EXAS stock has decreased by 44.4% and is now trading at $43.24.
View the best growth stocks for 2022 here.

Exact Sciences saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 11,540,000 shares, a decline of 14.6% from the May 15th total of 13,520,000 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is currently 5.7 days.
View Exact Sciences' Short Interest.

Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for Exact Sciences.

Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, April, 26th. The medical research company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.08. The medical research company had revenue of $486.57 million for the quarter, compared to analyst estimates of $461.86 million. Exact Sciences had a negative net margin of 40.26% and a negative trailing twelve-month return on equity of 21.82%. During the same period in the prior year, the company posted ($0.18) EPS.
View Exact Sciences' earnings history.

Exact Sciences updated its FY 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.99 billion-$2.03 billion, compared to the consensus revenue estimate of $2.01 billion.

141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Exact Sciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS).
View all of EXAS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.89%), ARK Investment Management LLC (8.23%), Sumitomo Mitsui Trust Holdings Inc. (3.23%), Capital World Investors (3.12%), Nikko Asset Management Americas Inc. (2.94%) and Baillie Gifford & Co. (2.48%). Company insiders that own Exact Sciences stock include Canada Pension Plan Investment, D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella, Scott C Johnson and Torsten Hoof.
View institutional ownership trends for Exact Sciences.

EXAS stock was sold by a variety of institutional investors in the last quarter, including Eventide Asset Management LLC, Nicholas Investment Partners LP, Bank of Nova Scotia, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Baillie Gifford & Co., Ensign Peak Advisors Inc, and Advisor Group Holdings Inc.. Company insiders that have sold Exact Sciences company stock in the last two years include Canada Pension Plan Investment, D Scott Coward, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Sarah Condella, and Torsten Hoof.
View insider buying and selling activity for Exact Sciences or view top insider-selling stocks.

EXAS stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Capital World Investors, Farallon Capital Management LLC, Vanguard Group Inc., New York State Common Retirement Fund, Ergoteles LLC, Zweig DiMenna Associates LLC, and First Trust Advisors LP.
View insider buying and selling activity for Exact Sciences or or view top insider-buying stocks.

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $43.24.

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $7.61 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595.63 million in net income (profit) each year or ($4.32) on an earnings per share basis.

Exact Sciences employs 6,500 workers across the globe.

Exact Sciences was founded in 1995.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for Exact Sciences is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at [email protected], or via fax at 608-284-5701.